A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation.

Targeting cancers with amplified or abnormally activated c-Met (hepatocyte growth factor receptor) may have therapeutic benefit based on nonclinical and emerging clinical findings. However, the eventual emergence of drug resistant tumors motivates the pre-emptive identification of potential mechanis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Nathan V Lee, Maruja E Lira, Adam Pavlicek, Jingjing Ye, Dana Buckman, Shubha Bagrodia, Sreesha P Srinivasa, Yongjun Zhao, Samuel Aparicio, Paul A Rejto, James G Christensen, Keith A Ching
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science (PLoS) 2012-01-01
Colecção:PLoS ONE
Acesso em linha:http://europepmc.org/articles/PMC3382171?pdf=render
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados